Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M69,830Revenue (TTM) $M11,717Net Margin (%)28.1Altman Z-Score6.6
Enterprise Value $M73,439EPS (TTM) $15.3Operating Margin %38.7Piotroski F-Score5
P/E(ttm)21.7Beneish M-Score-2.4Pre-tax Margin (%)36.9Higher ROA y-yN
Price/Book6.010-y EBITDA Growth Rate %24.8Quick Ratio1.8Cash flow > EarningsY
Price/Sales6.15-y EBITDA Growth Rate %28.9Current Ratio2.1Lower Leverage y-yY
Price/Free Cash Flow34.6y-y EBITDA Growth Rate %-1.3ROA % (ttm)15.0Higher Current Ratio y-yN
Dividend Yield %--PEG0.8ROE % (ttm)28.0Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M211ROIC % (ttm)23.8Gross Margin Increase y-yN

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

BIIB is held by these investors:

BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & Sec 2017-07-25Sell4,974$290.0116.58view
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & Sec 2017-07-19Sell7,758$28518.63view
Posner Brian SDirector 2017-06-09Sell1,084$256.3131.91view
Vounatsos MichelCEO 2017-05-01Buy1,402$271.3524.6view
DENNER ALEXANDER JDirector 2017-04-27Buy73,858$278.521.4view
Clancy Paul JExecutive VP and CFO 2017-04-25Sell9,892$29016.59view
Sandrock AlfredEVP CMO Neuro & Neurodegenerat 2017-04-03Sell1,981$274.0823.36view
Clancy Paul JExecutive VP and CFO 2017-03-13Sell9,891$291.5515.97view
Sandrock AlfredEVP CMO Neuro & Neurodegenerat 2017-03-01Sell973$290.0716.56view
Vounatsos MichelCEO 2017-02-27Buy1,333$285.3918.47view

Press Releases about BIIB :

Quarterly/Annual Reports about BIIB:

News about BIIB:

Articles On GuruFocus.com
6 Quality Stocks With High Business Predictability Ratings Oct 10 2017 
Wall Street on the Bullish Path Oct 05 2017 
AbbVie's Venclexta Achieves Primary Endpoint Sep 19 2017 
Steven Cohen Dives Into Array BioPharma Sep 13 2017 
David Dreman’s Top 5 Health Care Buys for the 2nd Quarter Aug 25 2017 
Steven Cohen Plunges Into Opioid Replacement Maker Pacira Pharmaceuticals Aug 24 2017 
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa C Aug 10 2017 
AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigment Aug 03 2017 
Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies Jul 28 2017 
Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies Jul 27 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat